HS-20117 + FOLFIRI

HS-20117 is a fully-human bispecific immunoglobulin G1 (IgG1)-like antibody targeting both EGFR (epidermal growth factor receptor) and MET. It is designed to inhibit tumor growth by simultaneously blocking the EGFR and MET signaling pathways, which are implicated in cancer cell proliferation and survival. HS-20117 is being investigated in combination with other drugs for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) with EGFR mutations and colorectal cancer (CRC) that is RAS/BRAF V600E wild type[1]. FOLFIRI is a chemotherapy regimen consisting of three drugs: folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Folinic acid enhances the effectiveness of fluorouracil; fluorouracil acts as an antimetabolite inhibiting DNA synthesis; irinotecan inhibits topoisomerase I, preventing DNA replication in rapidly dividing cells. FOLFIRI is primarily used to treat metastatic colorectal cancer but may also be used for other advanced gastrointestinal cancers[2][3][4][6]. The combination of HS-20117 with FOLFIRI aims to leverage targeted inhibition of key oncogenic pathways alongside cytotoxic chemotherapy for enhanced anti-tumor efficacy.

Other names

irinotecan with 5FU and folinic acidIrMdG